EBS - Emergent Biosolutions Non-GAAP EPS of $4.50 beats by $0.08 revenue of $723.2M beats by $46.28M

Emergent Biosolutions press release (NYSE:EBS): Q4 Non-GAAP EPS of $4.50 beats by $0.08. Revenue of $723.2M (+24.0% Y/Y) beats by $46.28M. Updated FY 2022 Guidance: Revenue now expected to range between $1.3-$1.4B, vs. prior guidance of $1.4-$1.5B, vs. consensus of $1.44B; Adjusted EBITDA to be in the range of $240-$300M; Gross Margin reaffirmed at 47% - 51%; and Adjusted Net Income to be $95 - $140M vs. prior guidance of $135-$180M.

For further details see:

Emergent Biosolutions Non-GAAP EPS of $4.50 beats by $0.08, revenue of $723.2M beats by $46.28M